Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingavirin Forte in Influenza and ARVI
NCT07420985Phase 2Recruiting
- Sponsor
- Valenta Pharm
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Ingavirin in influenza, acute respiratory viral infection (ARVI), sponsored by Valenta Pharm. Started Oct 2025; status: recruiting.
02
Drugs
Ingavirin
03
Conditions
influenzaacute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT07420985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07420985.